Sinntaxis nya logga.png
 

is committed to discovering, developing and commercialising novel therapeutics that enhance recovery of brain functions after stroke.

 
Logga sinntaxis.png
 

ABOUT US

Magnolia.png

Sinntaxis was founded 2017 by scientists at Lund University and LU Holding AB. The company is managed by a team with vast experience in neuroscience/stroke research and pharmaceutical drug development and business development.

Sinntaxis has an established discovery platform for preclinical studies of stroke recovery, and has filed IP on the use of negative allosteric modulators of the metabotropic glutamate receptor 5 for the treatment of stroke recovery.

Sinntaxis has established a global network of Key Opinion Leaders ranging from experimental research to clinical trial in stroke recovery.

Logga sinntaxis.png
 
pexels-photo-167300.jpeg

17 million individuals are afflicted by stroke every year



5 million are in need of daily care due to life-long sensory, motor and cognitive disabilities

Research & development


Stroke is treated within hours after onset with removal of the obstructive clot in the brain vessels, but less than 10% of the stroke patients receive this therapy. There are no approved drugs that support rehabilitation and that enhance recovery of brain function after stroke. All stroke patients could be eligible for this treatment.

 

 

The Sinntaxis Approach

The graph shows improved restoration of brain function using therapy developed by Sinntaxis.

Employing mGlur5 inhibitors to restore brain function after stroke:

  • mGluR5 activation is detrimental for recovery of lost brain functions after stroke
  • mGluR5 inhibitors enhance recovery of lost brain functions
  • mGluR5 inhibitors beneficially remodel brain connectivity by synaptic remodelling
  • Start of treatment an extended period after brain insult is still effective
  • Combined treatment of mGluR5 inhibitors with training synergistically enhances recovery
 
Uppdaterad graf.png
 

NEWS

Logga sinntaxis.png
 

Press release
[2018-03-13]

Michael Oredsson appointed CEO of Sinntaxis AB

The former CEO of public companies BioInvent och Probi, Michael Oredsson, has been appointed CEO of Sinntaxis AB, a young biotech company in Lund developing a new drug for stroke recovery. Lars Grundemar, with extensive international experience from the pharma industry, has been appointed Chairman of the Board. The company is based on research conducted by Tadeusz Wieloch and his group at Lund university.

Read more here

Click here to read the press release in Swedish

 

Press release [2018-08-10]

Sinntaxis secures option for Phase 2 -ready molecule helping patients to recover brain function after stroke

Sinntaxis nya logga.png

MANAGEMENT & BOARD OF DIRECTORS

  Michael Oredsson   Chief Executive Officer

Michael Oredsson
Chief Executive Officer

Michael Oredsson has close to twenty years experience as CEO of life science companies in Sweden, Australia and Norway and serves, or has served, as Chairman of the board or board member of several companies. During the eighties and nineties he worked in leading management positions in companies such as Pharmacia, M&M/Mars and Nestlé.
Michael is a graduate of Lund University in International Business Administration.

  Tadeusz Wieloch, PhD   Board Member & Chief Scientific Officer

Tadeusz Wieloch, PhD
Board Member & Chief Scientific Officer

Tadeusz Wieloch is Professor at Lund University and co-founder of Sinntaxis. He has published more than 200 articles in the area of experimental stroke, cardiac arrest and brain trauma. During the last 10 years a particular focus has been on the mechanisms of brain plasticity and recovery of brain function after stroke.

  Lars Grundemar, MD, PhD   Chairman of the Board

Lars Grundemar, MD, PhD
Chairman of the Board

Lars Grundemar brings extensive leadership experience from the pharmaceutical industry developing medicines across therapeutic areas, including Neuroscience applications. Previously Head of Experimental Medicine, Ferring Pharmaceuticals, former positions at AstraZeneca (Sweden) and Novartis (Switzerland) and Pharmacia (Sweden, Italy and USA). Adjunct Professor Clinical Pharmacology, Lund University, Sweden. Before industry clinician and research scientist predominantly in Neuroscience research.

 

 
  Christine Widstrand, PhD   Board Member

Christine Widstrand, PhD
Board Member

Christine Widstrand is Executive Vice President at LU Holding AB and responsible for the Life Science portfolio. She holds a PhD in Analytical Chemistry from Lund University. With a background as CEO and founder of several Biotech Companies, she has gained over twenty years of experience in business development, venture capital raising, international sales and marketing, licensing and organisational and quality management. Dr Widstrand has many years of experience in board work, both as a member and as a Chairman.

  Roger Olsson, PhD   Board Member

Roger Olsson, PhD
Board Member

Roger Olsson is Professor of Chemical Biology at Lund University and co-founder of Sinntaxis. Prior to his current position in academia, Dr. Olsson was working in leading positions for more than 20 years in the pharmaceutical and biotech industries, at ACADIA Pharmaceuticals he was involved in the discovery of the drug NUPLAZID® (pimavanserin). Roger has directed multiple projects and brought several new compounds from concept into clinical trials with focus on GPCRs and nuclear hormone receptors in psychiatric and neurodegenerative diseases, pain, and ophthalmology.

 
 
Logga sinntaxis.png

Contact Us

sinntaxis@gmail.com

SmiLe incubator, Medicon Village, Scheelevägen 2, 223 81 Lund                                                                  

CEO Michael Oredsson
+46707188930